Linked Life Data

16896967

Source:http://linkedlifedata.com/resource/pubmed/id/16896967

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2006-12-29
pubmed:abstractText
We reported previously that pigeon cytochrome c-derived peptides (Pan-IA), which bind broad ranges of MHC class II molecules efficiently, activate T helper (Th) function in mice. In an experimental model, Pan-IA DNA vaccines augmented antitumor immunity in tumor antigen-immunized mice. To elicit more potent antitumor immunity and to eradicate tumors in a therapeutic setting, Pan-IA-loaded dendritic cells (DCs) were inoculated in combination with vaccines including ovalbumin (OVA) antigen DNA in tumor-bearing mice. Seventy percent of the immunized mice survived tumor-free for at least 4 months after treatment. In contrast, mice vaccinated with OVA DNA, either with or without naïve DCs, did not eliminate the tumors and died within 5 weeks. Only in mice vaccinated with OVA DNA and Pan-IA-loaded DCs were both cytotoxic and helper responses specific for OVA induced at the spleen and tumor sites as well as at the vaccination sites. Furthermore, accumulation of OVA-specific CD4(+) and CD8(+) T lymphocytes and interferon-gamma-mediated anti-angiogenesis were observed in the tumors of these mice. Thus, the combined vaccination primed both tumor-specific cytotoxicity and helper immunity resulting in augmented tumor lysis ability and anti-angiogenic effects. This is the first report to show that most established tumors were successfully eradicated by collaboration of potent antitumor immunity and anti-angiogenic effects by vaccination with tumor antigens and helper-activating analogs. This novel vaccination strategy is broadly applicable, regardless of identifying helper epitopes in target molecules, and contributes to the development of therapeutic cancer vaccines.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0340-7004
pubmed:author
pubmed:issnType
Print
pubmed:volume
56
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
331-42
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:16896967-Animals, pubmed-meshheading:16896967-Antigens, Neoplasm, pubmed-meshheading:16896967-Cancer Vaccines, pubmed-meshheading:16896967-Cell Line, Tumor, pubmed-meshheading:16896967-Cell Proliferation, pubmed-meshheading:16896967-Columbidae, pubmed-meshheading:16896967-Cytochromes c, pubmed-meshheading:16896967-DNA, Neoplasm, pubmed-meshheading:16896967-Dendritic Cells, pubmed-meshheading:16896967-Disease Models, Animal, pubmed-meshheading:16896967-Epitopes, pubmed-meshheading:16896967-Female, pubmed-meshheading:16896967-Flow Cytometry, pubmed-meshheading:16896967-Immunohistochemistry, pubmed-meshheading:16896967-Interferon-gamma, pubmed-meshheading:16896967-Lymphocytes, pubmed-meshheading:16896967-Mice, pubmed-meshheading:16896967-Mice, Inbred C57BL, pubmed-meshheading:16896967-Neoplasms, pubmed-meshheading:16896967-Ovalbumin, pubmed-meshheading:16896967-Peptide Fragments, pubmed-meshheading:16896967-Spleen
pubmed:year
2007
pubmed:articleTitle
Successful tumor eradication was achieved by collaboration of augmented cytotoxic activity and anti-angiogenic effects following therapeutic vaccines containing helper-activating analog-loaded dendritic cells and tumor antigen DNA.
pubmed:affiliation
Department of Surgery, Shiga University of Medical Science, Seta-tsukinowa, Otsu 520-2192, Japan.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't